{"schema_version":"1.0","type":"article","title":"The $190 Billion Business Beyond Weight-Loss Drugs: Abdominal Fat Reduction Still Has No Approved Drug","url":"https://drugnews.com.tw/articles/2026-11-16-caliway-body-economy-after-weight-loss-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-16-caliway-body-economy-after-weight-loss-en.md","lang":"en","date":"2026-11-16","publish_at":"2026-11-16T08:00:00+08:00","updated_at":"2026-11-16","category":"商業分析系列","topic":"商業分析系列","tags":["GLP-1","CBL-514","Body Economy"],"summary":"The Last Mile After Weight Loss","key_points":["In 2026, Roche both invested and withdrew: it licensed Hanmi Pharmaceutical’s UCN2 candidate HM17321 in August for $190 million upfront, with a potential total of approximately $2.3 billion; stopped obesity development of emugrobart in September; and acquired global rights to Rona Therapeutics’ ALK7 RNAi program in October for up to approximately $1.16 billion.[1][2][3]","Patients want a flatter abdomen without hollow cheeks, and a lighter body without losing muscle and strength. Weight-loss injections lower body weight, but cannot choose where fat comes off or solve maintenance after discontinuation on their own.","After weight loss, quality, maintenance and body shape become the next areas of competition. This is the last mile after weight loss, and what DrugNews calls the Body Economy."],"facts":[],"sections":[],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/articles/caliway-body-economy-after-weight-loss-en/cover.jpeg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-16）。The $190 Billion Business Beyond Weight-Loss Drugs: Abdominal Fat Reduction Still Has No Approved Drug。https://drugnews.com.tw/articles/2026-11-16-caliway-body-economy-after-weight-loss-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"client_approved":true,"social":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “In 2026, Roche both invested and withdrew: it licensed Hanmi Pharmaceutical’s UCN2 candidate HM17321 in August for $190 million upfront, with a potential total of approximately $2.3 billion”?","a":"In 2026, Roche both invested and withdrew: it licensed Hanmi Pharmaceutical’s UCN2 candidate HM17321 in August for $190 million upfront, with a potential total of approximately $2.3 billion; stopped obesity development of emugrobart in September; and acquired global rights to Rona Therapeutics’ ALK7 RNAi program in October for up to approximately $1.16 billion.[1][2][3]"},{"q":"What are the key developments in “Patients want a flatter abdomen without hollow cheeks, and a lighter body without losing muscle and strength”?","a":"Patients want a flatter abdomen without hollow cheeks, and a lighter body without losing muscle and strength. Weight-loss injections lower body weight, but cannot choose where fat comes off or solve maintenance after discontinuation on their own."},{"q":"What are the key developments in “After weight loss, quality, maintenance and body shape become the next areas of competition”?","a":"After weight loss, quality, maintenance and body shape become the next areas of competition. This is the last mile after weight loss, and what DrugNews calls the Body Economy."}]}